Sort by
Refine Your Search
-
have been awarded and Birmingham is taking a national leadership role in driving transformative health research and clinical innovation, including in the LifeArc Centre for Acceleration of Rare Disease
-
. The Materials for eXtremes (M4X) research group (https://more.bham.ac.uk/M4X/ ) investigates new alloys for extreme environments from fusion & fission reactors, to aerospace gas turbines and concentrated solar
-
whether these reinstatement opportunities improve accuracy relative to standard, non-adaptive lineups, and how witnesses naturally explore faces under these conditions. A core innovation of the project is
-
loosening, infection) derive from a top-down, one-size-fits-all approach to implants; CUSTOM plans to invert this approach, based on combining computational, patient-specific design and additive manufacturing
-
impactful problems—from designing and analysing coiled‑coil architectures and developing molecular glues that reprogramme protein interactions, to resolving the structure and dynamics of photosynthetic
-
? This project provides extensive interdisciplinary training from subject experts and industry, including in behavioural experimental design and statistical modelling; computer vision and AI techniques
-
of complex gut microbiota while overcoming the limitations of donor-derived materials. These systems will be designed to be stable, reproducible, and deployable, creating new opportunities for microbiome-based
-
, patient-specific design and additive manufacturing to offer complex, custom designs and structures. The project also incorporates multi-functionality as well as blended experimental and in-silico testing
-
postdoctoral researchers and has proven track-record in mentoring and supporting the development of early-career researchers. The profile and research interests of the group may be found at: https
-
-specific design and additive manufacturing to offer complex, custom designs and structures. The project also incorporates multi-functionality as well as blended experimental and in-silico testing